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AbstrACt
Objectives and design A novel risk stratification 
algorithm estimating risk of death in patients with relapsed 
multiple myeloma starting second- line treatment was 
recently developed using multivariable Cox regression of 
data from a Czech registry. It uses 16 parameters routinely 
collected in medical practice to stratify patients into four 
distinct risk groups in terms of survival expectation. To 
provide insight into generalisability of the risk stratification 
algorithm, the study aimed to validate the risk stratification 
algorithm using real- world data from specifically designed 
retrospective chart audits from three European countries.
Participants and setting Physicians collected data from 
998 patients (France, 386; Germany, 344; UK, 268) and 
applied the risk stratification algorithm.
Methods The performance of the Cox regression model 
for predicting risk of death was assessed by Nagelkerke’s 
R2, goodness of fit and the C- index. The risk stratification 
algorithm’s ability to discriminate overall survival across 
four risk groups was evaluated using Kaplan- Meier curves 
and HRs.
results Consistent with the Czech registry, the 
stratification performance of the risk stratification 
algorithm demonstrated clear differentiation in risk of 
death between the four groups. As risk groups increased, 
risk of death doubled. The C- index was 0.715 (95% CI 
0.690 to 0.734).
Conclusions Validation of the novel risk stratification 
algorithm in an independent ‘real- world’ dataset 
demonstrated that it stratifies patients in four subgroups 
according to survival expectation.
IntrOduCtIOn
The management of multiple myeloma (MM) 
can be challenging owing to the heteroge-
neous nature of patient’s characteristics, the 
disease course and the array of treatment regi-
mens that patients may receive.1 2 Although 
many patients respond well to current first- 
line (1L) treatments, these are not curative 
and most patients will relapse or become 
refractory.3 4 A report from a European chart 
review has found that while a high propor-
tion of patients with MM received at least one 
line of active treatment (95%), this decreased 
significantly with further lines of treatment; 
61% received a second line and 15% received 
a fourth or further line.5 The type of treat-
ment and treatment sequence also varied 
considerably at each line.5
Defining the prognosis of patients with 
MM is increasingly challenging. Physicians 
may consider a range of patient- related and 
disease- related factors when trying to assess 
MM prognosis. These can include age, time 
to progression, best response achieved, cyto-
genetics and Eastern Cooperative Oncology 
strengths and limitations of this study
 ► The risk stratification algorithm was validated in a 
real- world dataset containing information on pa-
tients with symptomatic multiple myeloma from 
France, Germany and the UK.
 ► Using real- world data from the Czech Registry of 
Monoclonal Gammopathies, HRs for independent 
predictors of overall survival were derived from a 
Cox model and individual patient scores were cal-
culated for total risk.
 ► The performance of the Cox regression mod-
el for predicting risk of death was assessed by 
Nagelkerke’s R2, goodness of fit and the C- index.
 ► A comparison of the HRs across validation datasets 
was used to indicate the extent to which scores 
could be reliably interpreted in different countries/
settings.
 ► The current analysis is limited in that it used a mix 
of Cox model performance (R2, C- index) and simply 
computed HRs to compare risk groups; currently, 
there are no established measures for assessing 
risk stratification algorithm performance.
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Group (ECOG) performance status, as well as comorbid-
ities, previous treatment history (including efficacy and 
tolerability) and the type of relapse.2 6 In addition to these 
factors, validated prognostic and predictive tools are 
needed in MM to standardise risk stratification of patients 
and ultimately improve risk assessment.
The International Staging System (ISS) and the revised 
ISS (R- ISS) have been developed to indicate prognosis in 
MM and are based on the strongest known predictors at 
diagnosis.7–9 The ISS uses a three- stage classification at 
diagnosis to predict survival based on serum albumin and 
serum β-2 microglobulin (Sβ2M) levels7 8 and the R- ISS 
includes cytogenetic abnormalities (CA) and lactate dehy-
drogenase (LDH) levels in addition to Sβ2M and serum 
albumin levels to refine the definition of the disease 
stage.9 10 Neither of these tools, however, fully reflect the 
typical clinical approach to assessing patient prognosis at 
first relapse11 nor do they address the experience of the 
patient during newly diagnosed MM and characteristics 
of the patient as they relapse. The ISS and R- ISS are there-
fore less relevant for holistic risk assessment in this setting. 
The ISS and R- ISS were designed to predict survival based 
on parameters measured at diagnosis.7 9 Although the 
prognostic value of the R- ISS has been demonstrated in 
both newly diagnosed patients and those with relapsed or 
refractory MM,12 13 it does not take account of important 
indicators available to physicians at first relapse such 
as the efficacy and safety of 1L treatment. In addition, 
patient characteristics at initiation of second- line (2L) 
treatment differ significantly from those at diagnosis (eg, 
many patients die during frontline therapy). Therefore, 
there is a need for specifically designed risk assessment 
tools.14
Given the need for specifically designed tools to aid 
medical decision- making in MM at first relapse, a novel 
risk stratification algorithm has been developed using 
real- world data from the Czech Registry of Monoclonal 
Gammopathies (RMG) for patients with relapsed MM 
initiating 2L treatment.15 16 The risk stratification algo-
rithm uses 16 predictors to stratify patients into four risk 
groups with profoundly different survival expectations. It 
is the first tool that was designed to include both frailty 
assessment and disease aggressiveness in a single algo-
rithm to reflect holistic patient- specific risk assessment.
Two manuscripts have recently been published to 
describe the development of the risk stratification algo-
rithm. Hájek et al provided an overview of the algorithm 
development and addressed how the results can be inter-
preted from a clinical decision- making perspective.16 
Recently, a manuscript describing in detail the method-
ology used to develop the risk stratification algorithm has 
been published.15 The methodology manuscript explains 
the processes involved in constructing risk stratification 
and prognostic tools in oncology. To provide insight 
into the generalisability of this new risk stratification 
algorithm and its potential for use in clinical practice, 
external validation was required to evaluate its perfor-
mance in independent datasets. A bespoke retrospective 
chart review cohort study was conducted to collate data 
from patients in France, Germany and the UK for this 
purpose. Individual data from these three countries and 
the pooled validation population were compared with 
the development cohort and differences in disease char-
acteristics and treatment patterns were examined. In this 
manuscript, we report the validation of the risk stratifi-
cation algorithm in detail using real- world data sources 
from France, Germany and the UK, with an assessment 
of its performance to predict the risk of death in patients 
with relapsed MM.
MethOds
description of the risk stratification algorithm
A Cox model was developed using a conceptual model in 
MM which combined a systematic literature review and 
physician judgement (using a Delphi process) to select 
candidate predictors, followed by a backward selection 
process using Akaike’s information criterion to iden-
tify the independent predictors of overall survival (OS) 
.17 HRs for OS of each predictor were derived from the 
Cox regression analysis. Risk scores were then calculated 
by multiplying the HRs for each predictor. The patient- 
specific score was used as a single variable to stratify 
patients into four risk groups; these were defined using 
the K- adaptive partitioning algorithm (total risk score 
≤3.0, group 1; >3.0 to ≤7.0, group 2; >7.0 to 15.4, group 
3; >15.4, group 4).
The risk stratification algorithm incorporated the 
following as predictors of OS that are available in routine 
clinical practice: age, albumin level, bone marrow plasma 
cell count, thrombocyte count, Sβ2M level, Sβ2M level 
at diagnosis, LDH level, LDH level at diagnosis, calcium 
level, time to next treatment, ECOG performance status, 
CA at diagnosis, extramedullary disease, new bone lesions 
(X- ray), refractory status and severe toxicities during 1L 
treatment (any grade 3 or 4 toxicity). All predictor values 
used in the risk stratification algorithm were measured 
at initiation of 2L treatment with the exception of CA, 
LDH and Sβ2M; the latter two predictors were measured 
at both diagnosis and initiation of 2L treatment. A corre-
sponding frailty score (defined by age and ECOG perfor-
mance status) and aggressiveness score (defined by all 
the identified predictors specifically linked to the disease 
characteristics) were calculated for each patient.
The data used to develop the risk stratification algo-
rithm were sourced from the Czech RMG.18
data analysis
Data for the validation were derived from patient medical 
chart audits in France, Germany and the UK. A bespoke 
retrospective chart review cohort study was designed to 
collect all of the real- world data required to validate the 
risk stratification algorithm. Participating physicians were 
oncologists, oncohaematologists and haematologists; in 
total, 60 physicians participated from France, 70 from 
Germany and 50 from the UK. Patients with symptomatic 
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MM were documented if they were initiated on 2L anti-
tumour drug treatment during 2013 (providing sufficient 
follow- up to collect survival outcomes). Relevant data 
were abstracted onto a study- specific case report form 
during the second and third quarters of 2017. Data from 
the individual countries were examined descriptively for 
population differences and pooled for the purpose of 
validation.
The baseline period was defined as the time between 
diagnosis and the initiation of 2L treatment. Patients 
were followed from diagnosis to death, end date of 
study inclusion (if not deceased) or date of last contact 
(if lost to follow- up). Recorded outcomes included OS, 
progression- free survival, time to disease progression and 
treatment response.
Real- world data were analysed on a descriptive basis. 
Continuous variables were summarised using descriptive 
statistics (number, mean, SD, median, minimum and 
maximum values). Categorical variables were reported 
as frequency counts and the percentage of individuals 
in corresponding categories. Survival outcomes were 
summarised with Kaplan- Meier curves and in terms 
of median (95% CI) survival and the restricted mean 
survival.
Multiple imputation was performed for missing 
values,19 but only for predictors in the risk stratification 
algorithm, and with the exception of CA. No outcomes 
data were imputed. Owing to the lack of methods by 
which Cox model performance measures may be pooled, 
five rounds of imputation were conducted and data in the 
third imputed set were analysed.
Validation procedure
The performance of the risk stratification algorithm was 
evaluated in terms of the predictive performance of the 
Cox regression model and stratification of patients for 
OS.
A detailed description of the statistical analysis on 
the performance methods has been described previ-
ously.15 The performance of the Cox regression model 
for predicting the risk of death was assessed according 
to the extent to which the variance in OS was explained 
by the selected predictors (Nagelkerke’s R2), as well as 
the discriminative power (Harrell’s concordance index; 
C- index): point estimate (95% CI).20 21 The discriminative 
power of the Cox regression model was regarded as accu-
rate if the C- index was ≥0.70.
The performance of the risk stratification algorithm for 
stratifying patients in groups by OS was analysed by eval-
uating OS by risk group (using Kaplan- Meier curves) and 
HRs comparing risk groups. A comparison of the HRs 
across validation datasets was used to indicate the extent 
to which scores could be reliably interpreted in different 
countries/settings.
Patient frailty (based on age and ECOG performance 
status) and disease aggressiveness (based on all other 
predictors in the model) in different risk groups and the 
relationship between them across risk groups were also 
investigated.
Patient and public involvement statement
Data for the validation cohort were derived retrospec-
tively from patient medical chart audits. As such, patients 
and the general public were not involved in this study.
results
retrospective chart review
Chart data from a total of 998 patients were collected 
(France, 386; Germany, 344; UK, 268). The characteristics 
of these patients at diagnosis, including the 16 parameters 
used in the risk stratification algorithm, are summarised 
by country in table 1. Additional parameters not included 
in the risk stratification algorithm are described in online 
supplementary table S1. Certain between- country differ-
ences were observed (not compared statistically), such as 
a tendency for lower ISS and higher ECOG performance 
status scores in France versus Germany or the UK. In the 
validation cohort, 46.0% of patients had a prior stem cell 
transplant (SCT) and 11.5% of patients had an SCT at 
both 1L and 2L. A summary of the characteristics that 
were included in the risk stratification algorithm (pooled 
across the three countries) has been previously published 
alongside data from the original RMG dataset, and a 
number of discrepancies highlighted.16 Proportionally 
more patients in the validation cohort than in the Czech 
development cohort had elevated LDH levels, hypercal-
caemia and higher bone- marrow plasma cell counts and 
bone lesions, all of which are associated with an increased 
overall risk of death. However, this was mitigated to some 
extent by the fact that proportionally fewer patients in the 
validation cohort than in the Czech development cohort 
had proven refractory to thalidomide or had experienced 
grade 3–4 toxicity during 1L treatment.16
Cox model performance analysis
The point estimate for the C- index in the validation 
cohort was 0.715 (95% CI 0.690 to 0.734—a score of 
0.5 represents total random predictions; a score of 1 
represents a perfectly discriminating model; a good 
discriminating model has a score of >0.70). The R2 value 
for the validation set was 0.283 (possible scores range 
between 0 and 1 for a model that explains 0%–100% of 
the observed variation) based on 437 events observed in 
998 patients. For comparison, the R2 for the Czech devel-
opment cohort was 0.253 (737 events in 1418 patients).
stratification of patients
The distributions of patients across the four risk groups 
in the validation cohort and the original Czech RMG 
dataset have been described previously16; distribution 
was a little more even in the validation cohort than the 
RMG dataset, which was more skewed towards the lower 
risk groups. Patient characteristics at diagnosis and at the 
initiation of 2L treatment by risk group are summarised 
copyright.
 o
n
 Septem
ber 8, 2020 at University of G
lasgow. Protected by
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-034209 on 14 July 2020. Downloaded from 
4 Hájek R, et al. BMJ Open 2020;10:e034209. doi:10.1136/bmjopen-2019-034209
Open access 
Table 1 Patient characteristics included in the risk stratification algorithm by country
Characteristic Total (n=998) France (n=386) Germany (n=344) UK (n=268) HR* P value†
Frailty score
Parameters included in risk stratification algorithm
As measured at initiation of 2L treatment unless otherwise stated
1.015   Continuous 
variable
Age (years) 0.0002
  ≤65 456 (45.7) 159 (41.2) 143 (41.5) 154 (57.5)
  66–75 369 (37.00) 145 (37.6) 146 (42.4) 78 (29.1)
  >75 173 (17.3) 82 (21.3) 55 (16.0) 36 (13.5)
  Mean (SD) 66.4 (10.2) 67.6 (10.0) 66.5 (10.1) 64.4 (10.1)
  Median (IQR) 67 (59–74) 68 (60–75) 68 (59–74) 64 (57–73)
ECOG performance status     Categorical 
variable
  0 144 (14.4) 44 (11.4) 47 (13.7) 53 (19.8) –
  1 566 (56.7) 210 (54.4) 191 (55.5) 165 (61.6) 1.667 0.0011
  2 258 (25.9) 114 (29.5) 98 (28.5) 46 (17.2) 2.123 <0.0001
  3–4 30 (3.0) 18 (4.7) 8 (2.3) 4 (1.5) 3.708 <0.0001
Albumin (g/dL) 0.846   Continuous 
variable
  <3.5 509 (51.0) 157 (40.7) 170 (49.4) 182 (67.9) 0.0095
  ≥3.5 489 (49.0) 229 (59.3) 174 (50.6) 86 (32.1)
  Mean (SD) 3.5 (0.9) 3.7 (1.1) 3.5 (1.0) 3.3 (0.5)
  Median (IQR) 3.4 (3.0–3.8) 3.6 (3.1–3.9) 3.5 (3.0–3.9) 3.2 (2.9–3.6)
Bone marrow plasma cell count (%) 1.008
  <20 240 (24.0) 131 (33.9) 51 (14.8) 58 (21.6) <0.0001
  20–70 668 (66.9) 239 (61.9) 261 (75.9) 168 (62.7)
  >70 90 (9.0) 16 (4.1) 32 (9.3) 42 (15.7)
  Mean (SD) 36.6 (22.7) 16 (4.1) 32 (9.3) 42 (15.7)
β2 microglobulin (mg/L) 1.063 (up to 
5.5 mg/L)
  Continuous 
variable with 
threshold  <3.5 339 (34.0) 160 (41.5) 109 (31.7) 70 (26.1) 0.0787
  3.5–5.5 405 (40.6) 165 (42.7) 122 (35.2) 118 (44.4)
  >5.5 254 (25.5) 61 (15.8) 114 (33.1) 79 (29.5)
  Mean (SD) 4.5 (2.5) 4.0 (2.1) 5.0 (3.1) 4.7 (1.9)
  Median (IQR) 3.9 (3.0–5.6) 3.7 (2.7–4.8) 4.1 (3.0–6.0) 4.2 (3.4–5.8)
β2 microglobulin—diagnosis (mg/L) 1.090 (up to 
5.5 mg/L)
  <3.5 369 (37.0) 186 (48.2) 107 (31.1) 76 (28.4) 0.0084
  3.5–5.5 389 (39.0) 138 (35.8) 140 (40.7) 111 (41.4)
  >5.5 240 (24.0) 62 (16.1) 97 (28.2) 81 (30.2)
  Mean (SD) 4.4 (2.3) 4.0 (2.3) 4.7 (2.4) 4.7 (1.9)
  Median (IQR) 3.9 (3.0–5.5) 3.6 (2.7–4.6) 4.0 (3.2–5.8) 4.4 (3.2–5.8)
Thrombocyte count (109 cells/L) 0.995 (up to 
150×109 cells)
  >100 867 (86.9) 343 (88.9) 271 (78.8) 253 (94.4) <0.0001
  ≤100 131 (13.1) 43 (11.1) 73 (21.2) 15 (5.6)
  Mean (SD) 180.3 (79.4) 176.8 (70.4) 168.4 (90.1) 200.7 (72.5)
  Median (IQR) 176 (121–212) 177.0 (125.0–209.0) 154.0 (110.0–207.0) 195 (146.0–245.0)
Continued
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Characteristic Total (n=998) France (n=386) Germany (n=344) UK (n=268) HR* P value†
LDH (U/L) 2.080 (>ULN)   Continuous 
variable with 
clinically 
established 
cut- off
  Below ULN‡ 817 (81.9) 320 (82.9) 302 (87.8) 195 (72.8)
  Above ULN‡ 180 (18.1) 66 (17.1) 42 (12.2) 73 (27.2) <0.0001
  Mean (SD) 303.5 (146.9) 288.8 (137.4) 274.7 (100.3) 361.7 (188.3)
  Median (IQR) 264.0
(201.0–362.0)
233.0 (200.0–361.0) 247.0 (200.0–320.0) 314 (219.0–415.0)
LDH at diagnosis (U/L) 1.297 (>360 U/L)
  Below ULN‡ 832 (83.4) 324 (83.9) 304 (88.4) 218 (76.1)
  Above ULN‡ 166 (16.6) 62 (16.1) 40 (11.6) 64 (23.9) 0.0904
  Mean (SD) 296.0 (157.7) 282.2 (147.5) 275.3 (132.0) 342.4 (189.5)
  Median (IQR) 246.0
(200.0–350.0)
230.0 (195.0–345.0) 240.0 (200.0–328.0) 297.0 (207.0–397.0)
Hypercalcaemia§ 1.406 
(>2.75 mmol/L)
  No 799 (80.1) 316 (82.1) 246 (71.5) 252 (88.1)
  Yes 199 (19.9) 69 (17.9) 98 (28.5) 32 (11.9) 0.0422
  Mean (SD) 3.4 (2.6) 3.3 (2.6) 4.0 (3.0) 2.9 (1.7)
  Median (IQR) 2.4
(2.2–2.9)
2.4 (2.3–2.7) 2.4 (2.2–3.9) 2.5 (2.3–2.8)
Time to initiation of 2L treatment (months) 1.112 (≤24 
months)
  >24 467 (46.8) 224 (58.0) 133 (38.7) 110 (41.0)
  ≤24 531 (53.2) 162 (42.0) 211 (61.3) 158 (59.0) 0.2858
CAs at diagnosis   Categorical 
variable
  Standard risk 332 (33.3) 122 (31.6) 143 (41.6) 67 (25.0) –
  High risk 209 (20.9) 74 (19.2) 68 (19.8) 67 (25.0) 1.643 0.0067
  NA¶ 457 (45.8) 190 (49.2) 133 (38.7) 134 (50.0) 1.081 0.6299
Extramedullary disease
  No 879 (88.1) 326 (84.5) 311 (90.4) 242 (90.4) –
  Yes 119 (11.9) 60 (15.5) 33 (9.6) 26 (9.7) 2.331 <0.0001
Refractory to previous treatment
  Non- refractory/
refractory to other 
regimens without 
new drugs
787 (78.9) 309 (80.1) 270 (78.5) 208 (77.6) –
  Refractory to 
bortezomib
123 (12.3) 53 (13.7) 47 (13.7) 23 (8.6) 1.533 0.0006
  Refractory to 
thalidomide
1 (0.1) – – 1 (0.4) 1.186 0.1446
  Refractory to other 
regimens with new 
drugs**,††
87 (8.7) 24 (6.2) 27 (7.8) 36 (13.4) 1.427 0.0776
New bone lesions
  No new lesions 396 (39.7) 206 (53.4) 107 (31.1) 83 (31.0) –
  >2 lesions at 
diagnosis and at 2L, 
or new lesions
602 (60.3) 180 (46.6) 237 (68.9) 185 (69.0) 1.271 0.0049
Severe toxicities during/before 1L treatment (highest grade experienced)
  0–2 879 (88.1) 356 (92.7) 281 (81.7) 240 (89.6) –
  3–4 119 (11.9) 28 (7.3) 63 (18.3) 28 (10.4) 1.145 0.0797
Data are n (%) unless otherwise stated.
*HRs for calculating individual risk score (based on Cox regression analysis of development cohort).
† The p values are associated with the effects of the predictors in the risk stratification algorithm (based on Cox regression analysis of the development cohort) and not related to the 
comparison of countries.
‡Upper limit of normal (ULN) in the Czech data was estimated to be 360 U/L.
§Hypercalcaemia in the Czech data was defined as >2.75 mmol/L.
¶Missing values were not imputed for cytogenetic abnormalities (CAs).
**‘New’ drugs include carfilzomib, daratumumab, elotuzumab, ixazomib, panobinostat, pomalidomide and thalidomide.
††Refractory to other regimens with new drugs—includes bortezomib plus thalidomide, lenalidomide only, bortezomib plus lenalidomide and lenalidomide plus thalidomide.
ECOG, Eastern Cooperative Oncology Group; 1L, first line; 2L, second line; LDH, lactate dehydrogenase; NA, not available.
Table 1 Continued
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Table 2 Base case analysis (imputed dataset 3) of overall survival in the validation cohort and in the development cohort
Validation cohort Development cohort
Risk group n
Median overall 
survival (months; 
95% CI) HR (95% CI) n
Median overall 
survival (months; 
95% CI) HR (95% CI)
1 178 NA
(NA–NA)
Reference 351 61.6
(51.7 to 71.4)
Reference
2 345 NA
(NA–NA)
1.868
(1.234 to 2.827)
596 29.6
(26.6 to 32.6)
2.24
(1.78 to 2.83)
3 249 39.8
(32.7 to 46.7)
4.613
(3.091 to 6.883)
318 14.2
(11.3 to 17.1)
4.30
(3.38 to 5.49)
4 226 16.2
(13.7 to 21.0)
8.514
(5.735 to 12.64)
153 5.9
(4.4 to 7.5)
10.88
(8.32 to 14.23)
Pooled 998 NA NA 1418 27.6
(25.0 to 30.0)
NA
NA, not available.
in online supplementary table S2. Differences between 
risk groups were identified for parameters such as age 
(a trend for increasing mean age with risk group) and 
transplant status (fewer transplants for patients in groups 
3 or 4). Both ISS at diagnosis and ECOG performance 
status scores at 2L initiation showed a tendency for higher 
values with increasing risk group.
OS by risk group in the validation dataset is shown in 
table 2 (alongside data for the Czech development cohort 
for comparison). It is notable that OS was considerably 
longer in the validation dataset than in the original Czech 
development cohort. As was the case with the original 
Czech development cohort, there was clear differentia-
tion between HRs for OS between the risk groups in the 
validation dataset. The HRs for differences in OS between 
patients in group 1 and in groups 2, 3 and 4 were 1.87, 
4.61 and 8.51, respectively.
Kaplan- Meier plots for OS for the pooled validation set 
(figure 1A) and by country (figure 1B), as well as by risk 
group for the validation (figure 1C) and development 
(figure 1D) cohorts, are shown. The OS curve for the 
pooled set is immature, as the median was not reached 
during follow- up (figure 1A). This was also the case in the 
French and German cohorts (figure 1B) and, as noted 
above, in risk groups 1 and 2 (figure 1C). Median OS in 
the UK cohort was 49.2 months.
Disease aggressiveness and patient frailty were key 
components of classification in the original development 
of the novel risk stratification algorithm (figure 2). A 
scatterplot of disease aggressiveness scores versus frailty 
scores in the overall validation cohort and Czech devel-
opment cohort is shown in figure 2A and B, respectively, 
demonstrating clear stratification by risk group in each 
cohort. Considering the groups in sequence from 1 to 4 
(online supplementary figure S1A–C), it seems that frailty 
scores were spread quite broadly from group 2 onwards 
(online supplementary figure S1B), whereas disease 
aggressiveness scores were only markedly spread in group 
4 (online supplementary figure S1C). Notably, consid-
eration of frailty and disease aggressiveness in group 4 
patients shows that the frailest patients are not necessarily 
experiencing the most aggressive disease, and vice versa. 
It could be expected that patients with both a high frailty 
and high aggressiveness score may not have been able to 
survive to reach 2L therapy.
Univariate Cox models showed that the HRs of death 
associated with each unit increase in the total risk scores, 
aggressiveness scores and frailty scores for the validation 
cohort were 1.018, 1.101 and 1.341, respectively (table 3). 
Some differences were observed between the frailty and 
aggressiveness scores among countries; for example, 
frailty scores were higher in the UK cohort than in the 
French or German cohort (1.674, 1.302 and 1.428 for UK, 
France and Germany, respectively).
dIsCussIOn
The novel risk stratification algorithm was developed 
using data from one of the largest existing registries of 
patients with MM and monoclonal gammopathies of 
unknown significance. The RMG contains detailed infor-
mation on a large number of patient characteristics and 
disease- related parameters recorded at diagnosis and at 
first relapse. It has mature OS data and is representative 
of the national and international patient populations. In 
order to ensure generalisability of this tool to all patients 
with relapsed MM, however, it was important to validate the 
tool in an independent cohort. We therefore conducted a 
bespoke retrospective chart review cohort study in order 
to collate data from patients in France, Germany and the 
UK to collect data for this purpose. The pooled valida-
tion population from these three countries was around 
two- thirds of the size of the development cohort and 
demonstrated significant differences in disease character-
istics.16 Despite these differences, results were consistent 
between the two datasets, which highlights the ability of 
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Figure 1 Kaplan- Meier plots for overall survival in (A) the pooled validation cohort, (B) by country and (C) by risk group 
(imputed dataset 3); (D) by risk group in the development cohort. NA, not available; OS, overall survival; Ref, reference value.
the risk stratification algorithm to perform independent 
of patient heterogeneity.
Differences were identified between the patient charac-
teristics at diagnosis across the three countries in the vali-
dation dataset. ISS suggested, for example, that patients 
in France had less severe disease than in Germany or 
the UK, while patients in the UK and France were more 
likely to have undergone transplantation than those in 
Germany. The heterogeneity of the validation population 
overall supports its value in demonstrating the generalis-
ability of the risk stratification algorithm for use in prac-
tice. It is interesting to note that there was not complete 
agreement between the scoring systems; nearly one- fifth 
of patients classified as ISS group III fell into risk groups 
1 and 2, for example, while 13% of those in the lowest 
risk category based on ISS at diagnosis were identified by 
the risk stratification algorithm as being in the top two 
risk groups.
The C- index for the validation dataset (0.715), 
which was similar to the Czech development cohort 
(0.723),15 indicated that the Czech development cohort 
demonstrated accurate discriminative power across the 
validation dataset; the discriminative power of the Cox 
regression model could be regarded as accurate if the 
C- index was ≥0.70.21 The Nagelkerke’s R2 values were 
similar, suggesting that the Czech development model 
was able to explain variance in OS to a comparable extent 
in the two cohorts.
With regards to stratification of the risk groups, the 
Kaplan- Meier curves were shown to separate from early 
on in both the development and validation cohorts. 
There was little overlap of the Kaplan- Meier estimates 
for OS in the four groups during follow- up (figure 1C), 
or of the 95% CIs for HRs comparing each risk group 
versus group 1, indicating how well the four groups were 
differentiated. A similar trend was observed in the devel-
opment cohort (figure 1D). As risk groups increased, the 
HRs doubled in both the development and validation 
cohorts, demonstrating consistency in risk stratification 
of patients. In the Czech development cohort, median OS 
reduced by half as risk groups increased; in the validation 
cohort, median OS was not reached in groups 1 and 2 and 
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Figure 2 Frailty versus disease aggressiveness score by risk group in the pooled dataset: (A) validation cohort; (B) 
development cohort. RSA, risk stratification algorithm.
reduced by half in the higher risk groups. Adjustment for 
2L treatment in the validation dataset had little impact on 
HRs for OS (data not shown). To put the HR results into 
context, it is worth considering corresponding data from 
the R- ISS. Palumbo et al reported HRs of 3.68 and 9.95 for 
R- ISS groups II and III, respectively, versus group I.9
Comparing the same risk groups in the validation and 
Czech RMG populations revealed notable differences in 
median OS in the two cohorts. However, detailed consid-
eration of outcomes in the two populations was impeded, 
to an extent, by the fact that median OS was not reached 
in several groups in the validation population during the 
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Table 3 Univariate Cox model score in the pooled validation cohort and by country
Total risk score Aggressiveness score Frailty score
Pooled 1.018 (1.015 to 1.020) 1.101 (1.083 to 1.120) 1.341 (1.287 to 1.398)
France 1.023 (1.017 to 1.029) 1.149 (1.101 to 1.198) 1.302 (1.224 to 1.384)
Germany 1.020 (1.015 to 1.024) 1.106 (1.077 to 1.136) 1.428 (1.314 to 1.552)
UK 1.017 (1.012 to 1.021) 1.090 (1.061 to 1.120) 1.674 (1.491 to 1.880)
Data are effect of score in terms of HRs (95% CI).
60- month follow- up. The higher OS values in the vali-
dation cohort may imply a somewhat healthier patient 
population than the Czech RMG cohort, but in terms 
of deaths related to relapsed MM that conclusion is not 
supported by some of the differences in predictive char-
acteristics already described. Variation in OS would be 
expected in different populations, owing to modifica-
tions in treatment regimens or in other factors such as 
comorbidities and lifestyle, but importantly the trend in 
survival expectations associated with the risk stratification 
algorithm risk- group stratification was common to both 
populations, as can be seen by the similarity of the HRs 
in each risk group when estimated relative to group 1 
patients in the same population (table 3). Median OS in 
all risk groups would be expected to increase as treatment 
regimens improve, but in the absence of a cure, the strat-
ification process will be clinically useful when paired with 
an understanding of outcomes associated with different 
treatments in each risk group. This validation process can 
boast a number of design strengths. Critically, the use of a 
large, heterogeneous validation population, with demon-
strated variability in populations across three different 
countries, ensured robustness of the validation approach. 
This population differed from the Czech development 
population with which the tool was initially developed, so 
the validation represented a good test of generalisability. 
The chart data were also recent, in order to maximise the 
relevance of the validation to current clinical practice.
There were also, inevitably, certain limitations of the 
study. In terms of the representativeness of the sample, 
as mentioned earlier it appears that the external vali-
dation cohort may have been healthier than the orig-
inal Czech RMG population, based on OS estimates. It 
is intended that the risk stratification algorithm will be 
validated in further groups of patients with relapsed MM 
in order to ensure that the tool’s performance has been 
evaluated across a wide spectrum of patients. Valida-
tion in Greek22 and Slovakian populations is underway; 
these feature relatively short OS measurements, and thus 
will help to address the issue of the disproportionately 
healthy current validation cohort. From a methodolog-
ical perspective, the current analysis used a mix of Cox 
model performance (R2, C- index) and simply computed 
HRs comparing risk groups, as there are no established 
measures for assessing risk stratification algorithm perfor-
mance. Finally, in terms of the data obtained, there were a 
high number of missing values for certain variables, such 
as Sβ2M at diagnosis and LDH and albumin at 2L. These 
particular parameters are not typically used to guide 
treatment, and thus are rarely tested in routine practice; 
such issues are difficult to avoid in studies relying on real- 
world data.
COnClusIOn
The risk stratification algorithm has now been validated 
in an independent European cohort. Consistent results 
in risk stratification have been demonstrated between 
the validation and development cohorts, in terms of HR 
and median OS differences across risk groups. This is 
the first specifically designed patient risk assessment tool 
that combines both frailty and aggressiveness metrics 
into a single score. Patient- specific risk as assessed by this 
tool can be used as a prognostic factor to tailor manage-
ment strategies for patients, based on burden of disease, 
capacity to benefit, urgency to treat and to aid decisions 
on the intensity of therapy.
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